Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 3 |
Fibrosis | D005355 | — | — | 1 | 2 | — | — | — | 3 |
Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | 1 | 2 | — | — | — | 3 |
Pulmonary fibrosis | D011658 | — | — | 1 | 2 | — | — | — | 3 |
Esophageal neoplasms | D004938 | — | C15 | 1 | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | — | — | — | 1 |
Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
Cholangiocarcinoma | D018281 | — | C22.1 | 1 | — | — | — | — | 1 |
Medulloblastoma | D008527 | — | — | 1 | — | — | — | — | 1 |
Rhabdomyosarcoma | D012208 | — | — | 1 | — | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Drug common name | TALADEGIB |
INN | taladegib |
Description | Taladegib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target protein smoothened. |
Classification | Small molecule |
Drug class | hedgehog signaling inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1 |
PDB | — |
CAS-ID | 1258861-20-9 |
RxCUI | — |
ChEMBL ID | CHEMBL2142592 |
ChEBI ID | — |
PubChem CID | 49848070 |
DrugBank | — |
UNII ID | QY8BWX1LJ5 (ChemIDplus, GSRS) |